Gynecologic oncology
-
Gynecologic oncology · Aug 2009
Randomized Controlled Trial Multicenter Study Comparative StudyTopotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Effective therapies with a low rate of side effects are warranted in the 2nd-line setting in ovarian cancer. Both topotecan and the alkylating agent treosulfan have demonstrated efficacy in this patient group and are broadly used in Germany. Therefore, we started a prospectively randomized phase III trial comparing these two drugs in early recurrent ovarian cancer. ⋯ This randomized phase III trial could detect superiority of topotecan versus treosulfan in patients with recurrent disease after platinum-paclitaxel combination therapy. Our experience indicates that optimization of systemic treatment could improve outcome even in this poor prognostic subgroup of patients with relapsed ovarian cancer.
-
Gynecologic oncology · Aug 2009
Case ReportsAnaphylactic shock during the sentinel lymph node procedure for cervical cancer.
Patent blue is a commonly used agent in the detection of sentinel nodes (SN) in solid cancer. Similar to any drug, it is possible to have an allergic reaction during surgery. Anaphylactic reactions to patent blue have been rarely reported especially in cervical cancer. ⋯ Surgeons and anesthetists must be aware of the potential allergic of patent blue during the SN procedure.
-
Gynecologic oncology · Aug 2009
Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
To evaluate the role of secondary cytoreductive surgery in the management of patients with isolated nodal recurrence of epithelial ovarian cancer. ⋯ In selected patients presenting with ILNR optimal cytoreduction is possible in most of the cases with low perioperative morbidity. Combined with post-operative treatment, SCS results in a favorable outcome. More data are needed to better define the role of surgery in these patients.
-
Gynecologic oncology · Aug 2009
Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
The aim of this trial was to investigate the efficacy and toxicity of a relative high-dose of topotecan combined with carboplatin in recurrent or persistent epithelial ovarian cancer (EOC). ⋯ The relative high-dose of topotecan combined with carboplatin was feasible and produced modest activity in recurrent or persistent EOC. The RR and survival data appear promising for the initially platinum-sensitive cohort and thus this regimen may be considered for further development in this patient.